Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

194824

Sigma-Aldrich

Borane dimethyl sulfide complex solution

2.0 M in toluene

Sinónimos:

BMS, Trihydro[thiobis[methane]]boron

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula lineal:
(CH3)2S · BH3
Número de CAS:
13292-87-0
Peso molecular:
75.97
Beilstein/REAXYS Number:
3663489
MDL number:
MFCD00013189
UNSPSC Code:
12352112
PubChem Substance ID:
24851335

reaction suitability

reagent type: reductant

concentration

2.0 M in toluene

density

0.856 g/mL at 25 °C

SMILES string

B.CSC

InChI

1S/C2H6S.BH3/c1-3-2;/h1-2H3;1H3

InChI key

RMHDLBZYPISZOI-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Reactant used as a regioselective reducing agent

Reactant involved in:
  • Hydroboration / oxidation
Synthesis of cage compounds

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Aquatic Chronic 3 - Asp. Tox. 1 - Eye Dam. 1 - Flam. Liq. 2 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 - STOT SE 3 - Water-react 1

target_organs

Central nervous system

supp_hazards

EUH014

Storage Class

4.3 - Hazardous materials which set free flammable gases upon contact with water

wgk_germany

WGK 3

flash_point_f

44.6 °F - closed cup

flash_point_c

7 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
61496TM
09996HJ
S46238
04806TH
S44928

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Saskia Ditisheim et al.
Inflammatory bowel diseases, 21(11), 2598-2604 (2015-08-06)
Inflammatory bowel diseases (IBD) are systemic conditions that commonly display extraintestinal manifestations. Inflammatory articular disease (IAD: axial or peripheral) is the most common extraintestinal manifestation. The aim of this study was to evaluate the prevalence and the clinical characteristics associated
Veena K Ranganath et al.
Arthritis care & research, 67(7), 929-939 (2015-01-13)
To evaluate the effect of sustained American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission on residual joint inflammation assessed by magnetic resonance imaging (MRI) and to secondarily evaluate other clinical definitions of remission, within an early seropositive
Isidoro González-Álvaro et al.
Rheumatology (Oxford, England), 54(7), 1200-1209 (2014-12-21)
The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in
Elin S Gray et al.
Oncotarget, 6(39), 42008-42018 (2015-11-03)
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors
Jeong Won Jang et al.
Hepatology (Baltimore, Md.), 61(6), 1809-1820 (2015-01-30)
The effect of viral suppression on long-term disease outcome after decompensation in patients with hepatitis B virus (HBV)-related cirrhosis has not been established. The aim of this study was to determine the long-term effect of antiviral therapy (AVT) in patients
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico